Quarterly ResultMay 8, 2026, 09:16 AM
BioAge Labs: Positive BGE-102 Phase 1 Data; Q1 Net Loss $22.3M
AI Summary
BioAge Labs reported its first quarter 2026 financial results, including a net loss of $22.3 million and collaboration revenue of $2.8 million. The company announced positive topline Phase 1 data for BGE-102, an oral NLRP3 inhibitor, demonstrating significant reductions in inflammatory biomarkers. BioAge Labs plans to initiate two Phase 2 proof-of-concept trials for BGE-102 in cardiovascular risk and diabetic macular edema by mid-2026, and completed an upsized public offering raising $132.3 million, extending its cash runway through 2029.
Key Highlights
- Positive topline Phase 1 data for BGE-102 showed median hsCRP reductions of 86%.
- 87–93% of participants on BGE-102 reached normalized hsCRP (<2 mg/L).
- Completed an upsized follow-on public offering, raising approximately $132.3 million.
- Q1 2026 net loss was $22.3 million, compared to $12.9 million in Q1 2025.
- Collaboration revenue increased to $2.8 million in Q1 2026 from $1.5 million in Q1 2025.
- Research and development expenses rose to $20.4 million in Q1 2026 from $11.1 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $384.9 million as of March 31, 2026.
- Existing cash is estimated to fund operations and capital expenses through 2029.
Price Impact
More from BIOA